title: Co-administration of SR141716 with peptide YY3-36 or oxyntomodulin has additive effects on food intake in mice.
abstract: BACKGROUND
  SR141716 has been shown to significantly inhibit food intake and reduce body weight by antagonizing CB(1) receptors. The gut hormones peptide YY(3-36) (PYY(3-36)) and oxyntomodulin (OXM) inhibit food intake through Y(2) and Glucagon-Like-Peptide (GLP)-1 receptors respectively.
  
  
  OBJECTIVE
  To determine the effects of co-administration of SR141716 with either PYY(3-36) or OXM in mice on food intake.
  
  
  METHODS
  Mice (n = 14 per group) were fasted for 16 h prior to study days and given two intraperitoneal injections: study 1, vehicle-saline, SR141716-saline, vehicle-PYY3-36 or SR141716-PYY3-36; study 2: vehicle-saline, SR141716-saline, vehicle-OXM or SR141716-OXM. Food was returned and measured following injections.
  
  
  RESULTS
  Co-administration of SR141716-PYY(3-36) or SR141716-OXM showed greater inhibition in food intake when compared with administration of SR141716, PYY(3-36) or OXM alone.
  
  
  CONCLUSIONS
  Our data show that SR141716 in combination with PYY(3-36) or OXM reduces food intake additively in mice.
authors.affiliation: Department of Metabolic Medicine, Faculty of Medicine, Imperial College London, Hammersmith Hospital, London, UK.
authors.forename: N E
authors.initials: NE
authors.lastname: White
authors.forename: W S
authors.initials: WS
authors.lastname: Dhillo
authors.forename: Y-L
authors.initials: YL
authors.lastname: Liu
authors.forename: C J
authors.initials: CJ
authors.lastname: Small
authors.forename: G A
authors.initials: GA
authors.lastname: Kennett
authors.forename: J V
authors.initials: JV
authors.lastname: Gardiner
authors.forename: M A
authors.initials: MA
authors.lastname: Ghatei
authors.forename: S R
authors.initials: SR
authors.lastname: Bloom
mesh_terms: D000818:Animals; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D004435:Eating / Q000187:drug effects* / Q000502:physiology; D005215:Fasting / Q000378:metabolism / Q000523:psychology; D051379:Mice; D009765:Obesity / Q000517:prevention & control; D053772:Oxyntomodulin / Q000008:administration & dosage / Q000494:pharmacology*; D010446:Peptide Fragments; D019894:Peptide YY / Q000008:administration & dosage / Q000494:pharmacology*; D010880:Piperidines / Q000008:administration & dosage / Q000494:pharmacology*; D011720:Pyrazoles / Q000008:administration & dosage / Q000494:pharmacology*; D000077285:Rimonabant; D016896:Treatment Outcome
chemical_list: D053772:Oxyntomodulin; D010446:Peptide Fragments; D010880:Piperidines; D011720:Pyrazoles; D019894:Peptide YY; C061785:peptide YY (3-36); D000077285:Rimonabant